Therapeutic potential of A 2 and A 3 adenosine receptor: A review of novel patented ligands

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 4, 2012, Pages 369-390

  Federico, Stephanie ^a   Spalluto, Giampiero ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

A 2A receptor; A 2B receptor; A 3 receptor; adenosine receptors; agonists; allosteric modulators; antagonists; GPCR

Indexed keywords

ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR ANTAGONIST; ADENOSINE A2B RECEPTOR; ADENOSINE A2B RECEPTOR AGONIST; ADENOSINE A2B RECEPTOR ANTAGONIST; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR AGONIST; ADENOSINE A3 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; XANTHINE DERIVATIVE; LIGAND; PURINERGIC RECEPTOR AFFECTING AGENT;

DRUG POTENCY; HUMAN; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG EFFECT; MALE; METABOLISM; PATENT;

ADENOSINE A2 RECEPTOR AGONISTS; ADENOSINE A2 RECEPTOR ANTAGONISTS; ADENOSINE A3 RECEPTOR AGONISTS; ADENOSINE A3 RECEPTOR ANTAGONISTS; DRUG DESIGN; HUMANS; LIGANDS; MALE; MOLECULAR STRUCTURE; PATENTS AS TOPIC; PURINERGIC AGENTS; RECEPTOR, ADENOSINE A3; RECEPTORS, ADENOSINE A2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84859560679     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.669375     Document Type: Review

References (100)

1. Fredholm BB. Adenosine receptors as drug targets. Exp Cell Res 2010;316:1284-8
2. Fredholm BB, Ijzerman AP, Jacobson KA, et al. International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001;53:527-52 (Pubitemid 33136237)
3. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006;5:247-64 (Pubitemid 43336037)
4. Trincavelli ML, Daniele S, Martini C. Adenosine receptors: what we know and what we are learning. Curr Top Med Chem 2010;10:860-77
5. Ciruela F, Albergaria C, Soriano A, et al. Adenosine receptors interacting proteins (ARIPs): behind the biology of adenosine signaling. Biochim Biophys Acta 2010;1798:9-20
6. Ongini E, Fredholm BB. Pharmacology of adenosine A2A receptors. TiPS 1996;17:364-72
7. Richardson PJ, Kase H, Jenner PG. Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease. TiPS 1997;18:338-44 (Pubitemid 27404661)
8. Baraldi PG, Tabrizi MA, Gessi S, Borea PA. Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility. Chem Rev 2008;108:238-63 (Pubitemid 351176408)
9. Basheer R, Strecker RE, Thakkar MM, McCarley RW. Adenosine and sleep-wake regulation. Prog Neurobiol 2004;73:379-96 (Pubitemid 39094087)
10. Mustafa SJ, Morrison RR, Teng B, Pelleg M. Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology. Handb Exp Pharmacol 2009;193:161-88
11. Shryock JC, Snowdy S, Baraldi PG, et al. A2A adenosine receptor reserve for coronary vasodilation. Circulation 1998;98:711-18 (Pubitemid 28387498)
12. Valls MD, Cronstein BN, Montesinos MC. Adenosine receptor agonists for promotion of dermal wound healing. Biochem Pharmacol 2009;77:1117-24
13. Brown RA, Spina D, Page CP. Adenosine receptors and asthma. Br J Pharmacol 2008;153:S446-56 (Pubitemid 351341018)
14. Fozard JR, Ellis KM, Villela Dantas MF, et al. Effects of CGS 21680, a selective adenosine A2A receptor agonist, on allergic airways inflammation in the rat. Eur J Pharmacol 2002;438:183-8 (Pubitemid 34241507)
15. Gessi S, Merighi S, Sacchetto V, et al. Adenosine receptors and cancer. Biochim Biophys Acta 2011;1808:1400-12
16. Adenosine Therapeutics, LLC. Agonists of A2A adenosine receptors for treating recurrent tumor growth in the liver following resection. WO130902; 2008
17. Cronstein BN, Peng ZS. Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening. US0123510; 2009
18. Guerrant RL, Linden JM, Warren CA, et al. Methods of treating enteritis, intestinal damage, and diarrhea from C. difficile with an A2A adenosine receptor agonist. WO124150; 2008
19. Rieger JM, Linden JM, Macdonald TL, et al. 2-Polycyclic propynyl adenosine analogs having A2A agonist activity. US7875595; 2011
20. Rieger JM, Linden JM, Macdonald TL, et al. 2-Polycyclic propynyl adenosineanalogs having A2A agonist activity. US7442687; 2008
21. PGX-Health, LLC. Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as A2A agonists. WO002917; 2011
22. CV Therapeutics, Inc. Use of A2A adenosine receptor agonists in the treatment of ischemia. WO063712; 2008
23. Novartis AG. Adenosine derivatives as A2A receptor agonists. WO031875; 2008
24. 2AAR.
25. Biovitrum AB. Therapeutic compounds. WO000743; 2008 Pro-drugs displayed an increment of 34% of oral bioavailability if compared with bioactive compounds and demonstrated higher affinity at low pH.
26. Biovitrum AB. Therapeutic compounds. WO000744; 2008
27. Muller C. Phosphorylated A2A receptor agonists. WO107598; 2007 Pro-drugs are preferentially metabolized in inflammation sites.
28. Moro S, Gao ZG, Jacobson KA, Spalluto G. Progress in the pursuit of therapeutic adenosine receptor antagonists. Med Red Rev 2006;26:131-59 (Pubitemid 43334639)
29. Kyowa Hakko Kirin Co., Ltd. Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients. NLM Identifier: NCT00957203. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-. Available from: http://clinicaltrials.gov/ct2/show/NCT00957203 [Last accessed 9 January 2012]
30. Schwarz Pharma, AG. 8-Ethinyl xanthine derivatives as selective A2A receptor antagonists. EP1939197; 2008
31. Neurocrine Biosciences, Inc. Substituted pyrimidines as adenosine receptor antagonists. WO116185; 2008
32. Vernalis R&D, Ltd. Pyrimidine compounds as purine receptor antagonist. US7875600; 2011
33. Palobiofarma, SL. 4-Aminopyrimidine derivatives and their adenosine A2A receptor antagonists. WO121418; 2011
34. Adenosine Therapeutics, LLC. Selective antagonists of A2A adenosine receptors. US0176858; 2008
35. Sigma-Tau Industrie Farmaceutiche Riunite SpA. Oxidated derivatives of triazolypurines useful as ligands for the adenosine A2A receptor and their use as medicaments. WO106145; 2010
36. Vernalis R&D, Ltd. Triazolo[4,5-d] pyrimidine derivatives and their use as purinergic receptor antagonists. US7405219; 2008
37. Vernalis R&D, Ltd. Pyrrolo[2,3-d] pyrimidine and their use as purinergic adenosine antagonists. US7598246; 2009
38. Domain Therapeutics. New adenosine receptor ligands and uses thereof. WO084425; 2010
39. CV Therapeutics, Inc. A2A adenosine receptor antagonists. WO070529; 2008
40. Johnson & Johnson. Methylene amines of thieno[2,3-d]pyrimidine and their use as adenosine A2A receptor antagonists. US0093702; 2010
41. Johnson & Johnson. Amides of thieno [2,3-d]pyrimidine and their use as adenosine A2A receptor antagonists. US0093714; 2010
42. Johnson & Johnson. Phenyl and heteroaryl substituted thieno[2,3-d] pyrimidine and their use as adenosine A2A receptor antagonists. US0093721; 2010
43. Johnson & Johnson. Heteroaryl and phenyl substituted thieno[2,3-d] pyrimidine as adenosine A2A receptor antagonists. US0093722; 2010
44. Harris JM, Neustadt BR, Liu H, et al. Amino-quinoxline and amino-quinoline compounds for use as adenosine A2A receptor antagonists. US0105513; 2011
45. Schering Corp. Adenosine A2A receptor antagonists. WO002596; 2008
46. Hodgson RA, Bertorelli R, Varty GB, et al. Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4, 3-e][1,2,4] triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression. J Pharmacol Exp Ther 2009;330:294-03 SCH420814 (preladenant) is in Phase II clinical trial for the treatment of PD.
47. Schering Corp. 1,2,4-Triazolo[4,3-c] pyrimidin-3-ones and pyrazolo[4,3-e] 1,2,4-triazolo[4,3-c]pyrimidin-3-ones compounds for use as adenosine A2A receptor antagonists. US0152256; 2011
48. King Pharmaceuticals, Inc. Adenosine A2A receptor antagonists. US0242672; 2008
49. Janssen Pharmaceuticals. Arylindenopyrimidines compounds and use as an adenosine A2A receptor antagonists. WO055308; 2009
50. Janssen Pharmaceuticals. Arylindenopyrimidines and their use as adenosine A2A. WO055548; 2009
51. 1AR.
52. Hoffman B, Chang H, Dall'Aglio E, Reaven GM. Desensitization of adenosine receptor-mediated inhibition of lipolysis. J Clin Invest 1986;78:185-90
53. Linden J. Adenosine in tissue protection and tissue regeneration. Mol Pharmacol 2005;67:1385-7 (Pubitemid 40594134)
54. Merighi S, Mirandola P, Varani K, et al. A glance at adenosine receptors: novel target for antitumor therapy. Pharm Ther 2003;100:31-48 (Pubitemid 37204899)
55. Harada H, Asano O, Hoshino Y, et al. 2-Alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: their synthesis and structure-activity relationships toward hepatic glucose production induced via agonism of the A2B receptor. J Med Chem 2001;44:170-9 (Pubitemid 32096661)
56. Polosa R, Blackburn MR. Adenosine receptors as targets for therapeutic intervention in asthma and chronic obstructive disease. Trends Pharmacol Sci 2009;30:528-35
57. Zhang Y, Dai Y, Wen J, et al. Detrimental effects of adenosine signalling in sickle cell disease. Nat Med 2011;17:79-87
58. King Pharmaceuticals, Inc. Adenosine A2B receptor agonists. US7691825; 2010
59. 2BAR agonist with a non-nucleosidic structure.
60. Gilead Sciences, Inc. Method of treating hepatic disease using A2B adenosine receptor antagonists. US0184002; 2011
61. Gilead Sciences, Inc. Prodrugs of A2B adenosine receptor antagonists. US0160162; 2011
62. Leung E. Methods of treating atherosclerosis. US0118276; 2011
63. Thompson RD. Substituted 8-[6-amino-3-pyridyl]xanthines. US7875608; 2011
64. PGX-Health, LLC. Substituted 8-[6-carbonylamine-3-pyridyl]xanthines as adenosine A2B antagonists. WO005871; 2011
65. Novartis, Insitutes for biomedical Research, Inc. Thiazole derivatives as A2B antagonists. US0233938; 2009
66. Hoffmann-La Roche, Inc. Substituted thiazolo[5,4-d]pyrimidine urea derivatives. US7947692; 2011
67. Laboratorios Almirall S.A. Imidazopyridine derivatives as A2B receptor antagonists. US7855202; 2010
68. Adenosine Therapeutics, LLC. Pyrrolo [3,2-d]pyrimidines that are selective antagonists of A2B adenosine receptors. US0082347; 2009
69. Cheong SL, Federico S, Venkatesan G, et al. The A3 adenosine receptor as multifaceted therapeutic target: pharmacology, medicinal chemistry and in silico approaches. Med Res Rev 2011 Published on-line
70. von Lubitz DKJE. Adenosine and cerebral ischemia: therapeutic future or death of a brave concept? Eur J Pharmacol 1999;371:85-102
71. Madi L, Ochaion A, Rath-Wolfson L, et al. The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition. Clin Cancer Res 2004;10:4472-9 (Pubitemid 38878891)
72. Madi L, Bar-Yehuda S, Barer F, et al. A3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition. J Biol Chem 2003;278:42121-30 (Pubitemid 37310479)
73. Ohana G, Bar-Yehuda S, Arich A, et al. Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101. Br J Cancer 2003;89:1552-8 (Pubitemid 37386614)
74. Gessi S, Merighi S, Varani K, et al. Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: focus on the A3 adenosine subtype. J Cell Physiol 2007;211:826-36 (Pubitemid 46683050)
75. Abbracchio MP, Rainaldi G, Giammarioli AM, et al. The A3 adenosine receptor mediates cell spreading reorganization of actin cytoskeleton, and distribution of Bcl-XL: studies in human astroglioma cells. Biochem Biophys Res Commun 1997;241:297-304 (Pubitemid 28020096)
76. Martin L, Pingle SC, Hallam DM, et al. Activation of the adenosine A3 receptor in RAW 264.7 cells inhibits lipopolysaccharide-stimulated tumor necrosi factor-alpha release by reducing calcium-dependent activation of nuclear factor-kappaB and extracellular signal-regulated kinase 1/2. J Pharmacol Exp Ther 2006;316:71-8 (Pubitemid 41832582)
77. La Sala A, Gadina M, Kelsall BL. G(i)-protein-dependent inhibition of IL-12 production is mediated by activation of the phosphatidylinositol 3-kinase-protein 3 kinase B/Akt pathway and JNK. J Immunol 2005;175:2994-9 (Pubitemid 41170517)
78. Schlozer-Schrehardt U, Zenkel M, Decking U, et al. Selective upregulation of the A3 adenosine receptor in eyes with pseudoexfoliation syndrome and glaucoma. Invest Ophthalmol Vis Sci 2005;46:2023-34
79. Can-Fite Biopharma Ltd. Use of A3 adenosine receptor agonist in osteoarthritis treatment. WO063538; 2007
80. Can-Fite Biopharma Ltd. Pharmaceuticals composition comprising A3 adenosine receptor agonist (IB-MECA/CF101) for treatment of psoriasis. WO027348; 2011
81. Can-Fite Biopharma Ltd. Adenosine A3 receptor agonists for the treatment of dry eye disorders. WO086044; 2007
82. Can-Fite Biopharma Ltd. Adenosine A3 receptor agonists for the reduction of intraocular pressure. WO134067; 2010
83. Gahl WA, Boehm M, St. Hilaire C, et al. Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders. WO123518; 2011
84. Ramot at Tel-Aviv University, Ltd. A3 adenosine receptor ligands for modulation of pigmentation. WO010306; 2011
85. Jacobson KA, Melman A. Purine derivatives as A3 receptor selective agonist. US0046166; 2011
86. 3AR.
87. Goblyos A, Brussee J, Ijzerman AP, et al. A3 adenosine receptor allosteric modulators. US0054476; 2009
88. Can-Fite Biopharma Ltd. A3 adenosine receptor allosteric modulators. US0144156; 2010
89. May LT, Briddon SJ, Hill SJ. Antagonist selective modulation of adenosine A1 and A3 receptor pharmacology by the food dye brilliant black BN: evidence for allosteric interactions. Mol Pharmacol 2010;77:678-86.109
90. Lane JR, Beukers MW, Mulder-Krieger T, IJzerman AP. The endocannabinoid 2-arachidonylglycerol is a negative allosteric modulator of the human A3 adenosine receptor. Biochem Pharmacol 2010;79:48-56
91. Addex Pharma, SA. Novel heteroaryl derivatives as antagonists of adenosine A3 receptor. WO010871; 2009
92. CV Therapeutics, Inc. A3 adenosine receptor antagonists. WO052310; 2009
93. Santaris Pharma, A/S. Adenosine receptors antagonists. US0062994; 2010
94. FM Therapeutics Co., Ltd. Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositions for the prevention and treatment of the inflammatory diseases containing the same as an active ingredient. WO108508; 2008
95. Avila M, Stone R. Effective delivery of cross-species A3 adenosine receptor antagonist to reduce intraocular pressure. WO045330; 2008 MRS3820 is a modified-nucleoside that shows high affinity both athuman and rat A3AR and is able to reduce IOP in both species.
96. Jacobson KA, Melman A, Wang BBR. A3 adenosine receptor antagonists and partial agonists. US0171130; 2011
97. Sanofi Aventis. Aminoquinoline derivatives and their use as adenosine A3 ligands. US0112092; 2011
98. King Pharmaceuticals R&D, Inc. Adenosine A3 modulators. US7470698; 2008 The most potent A3AR antagonist never reported.
99. King Pharmaceuticals R&D, Inc. Adenosine A3 receptor modulators. US7435740; 2008
100. Faust Pharmaceuticals. Pyrrolo[1,2-a] quinoxaline derivatives as adenosine A3 receptor modulators and uses thereof. US0093476; 2009